Medical Supply Chains: Questions Companies are Asking and Evolving Government Actions in the Aftermath of COVID-19

Supply chains have been upended in the wake of COVID-19. Companies have configured medical supply chains for cost, efficiency and competitive advantage. Governments are challenging these assumptions. U.S. officials have called for “re-shoring” supply chains, using new tariffs and subsidies for medical equipment, pharmaceuticals, and PPE. American, European and Asian governments are looking to use their purchasing power, new laws and regulations, and trade agreements to alter global supply relationships. This webinar will provide insights across a series of topics, including:

• What does “resiliency” mean for supply chains in the COVID-19?;
  
• Export restrictions imposed as a consequence of COVID-19;
• Prospects for nationalizing production and procurement requirements;
• Possible subsidies and tax incentives for “re-shoring” efforts;
• Regulatory barriers and obstacles to reconfiguration; 
• Trusted trading partner supply chain networks; and
• The role of national and international institutions.